Atlas Trials

To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)

Clinical trial NCT05814523 · WITHDRAWN

Trial details

NCT number
NCT05814523
Sponsor
Marinus Pharmaceuticals
Status
WITHDRAWN
Phase
Phase 3
Study type
INTERVENTIONAL
Refractory Status Epilepticus
Start date
2024-03-01
Primary completion
2024-08-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.